Entity Details

Primary name XYLT2
Entity type gene
Source Source Link

Details

PrimaryID64132
RefseqGeneNG_012175
SymbolXYLT2
Namexylosyltransferase 2
Chromosome17
Location17q21.33
TaxID9606
Statuslive
SourceGenomegenomic
SourceOriginnatural
CreationDate2001-04-13
ModificationDate2021-06-11

Ontological Relatives

UniProt IDsXYLT2_HUMAN

GO terms

Show/Hide Table
GOName
GO:0000139 Golgi membrane
GO:0000287 magnesium ion binding
GO:0005615 extracellular space
GO:0006024 glycosaminoglycan biosynthetic process
GO:0015012 heparan sulfate proteoglycan biosynthetic process
GO:0016021 integral component of membrane
GO:0030145 manganese ion binding
GO:0030158 protein xylosyltransferase activity
GO:0030203 glycosaminoglycan metabolic process
GO:0030206 chondroitin sulfate biosynthetic process
GO:0030210 heparin biosynthetic process
GO:0050650 chondroitin sulfate proteoglycan biosynthetic process

Diseases

Show/Hide Table
Disease IDSourceNameDescription
605822 OMIMSpondyloocular syndrome (SOS)A syndrome characterized by cataract, loss of vision due to retinal detachment, facial dysmorphism, facial hypotonia, normal height with disproportional short trunk, osteoporosis, immobile spine with thoracic kyphosis and reduced lumbal lordosis. The disease is caused by variants affecting the gene represented in this entry.
264800 OMIMPseudoxanthoma elasticum (PXE)A multisystem disorder characterized by accumulation of mineralized and fragmented elastic fibers in the skin, vascular walls, and Burch membrane in the eye. Clinically, patients exhibit characteristic lesions of the posterior segment of the eye including peau d'orange, angioid streaks, and choroidal neovascularizations, of the skin including soft, ivory colored papules in a reticular pattern that predominantly affect the neck and large flexor surfaces, and of the cardiovascular system with peripheral and coronary arterial occlusive disease as well as gastrointestinal bleedings. The gene represented in this entry acts as a disease modifier. PXE patients carrying causative ABCC6 mutations, manifest a more severe disease course characterized by earlier onset, frequent skin lesions and higher organ involvement, in the presence of XYLT2 variants.